A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as Single Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes after Hypomethylating Agent Failure
A study for patients with myelodysplastic syndrome (MDS) using study drug venetoclax
Sponsor: AbbVie
Enrolling: Male and Female Patients
IRB Number: AAAR1076
U.S. Govt. ID: NCT02966782
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the safety, pharmacokinetics (how much of the study drugs is present in your body at different times), and efficacy (how well the study treatment works) of venetoclax alone and of venetoclax in combination with azacitidine in subjects with higher-risk MDS after HMA-failure.
This study is closed
Joseph Jurcic, MD
Do You Qualify?
Have you been diagnosed with MDS? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator